Flc Capital Advisors Bristol Myers Squibb CO Transaction History

Flc Capital Advisors

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$47.98 - $54.4 $13,098 - $14,851	-273 Reduced 4.57%	5,695 $308,000
Q4 2023 Jan 18, 2024	SELL	$48.48 - $57.85 $13,428 - $16,024	-277 Reduced 4.44%	5,968 $306,000
Q3 2023 Jan 18, 2024	SELL	$57.89 - $64.73 $4,920 - $5,502	-85 Reduced 1.34%	6,245 $362,000
Q4 2022 Jan 27, 2023	SELL	$68.48 - $81.09 $1,232 - $1,459	-18 Reduced 0.28%	6,330 $455,000
Q3 2022 Oct 14, 2022	BUY	$0.13 - $76.84 $2 - $1,383	18 Added 0.28%	6,348 $451,000
Q3 2021 Oct 13, 2021	SELL	$59.17 - $69.31 $8,342 - $9,772	-141 Reduced 2.18%	6,330 $375,000
Q2 2021 Aug 12, 2021	BUY	$61.91 - $67.42 $8,729 - $9,506	141 Added 2.23%	6,471 $432,000
Q3 2019 Oct 29, 2019	SELL	$42.77 - $50.71 $97,729 - $115,872	-2,285 Reduced 26.52%	6,330 $321,000
Q2 2019 Aug 05, 2019	BUY	$44.62 - $49.34 $384,401 - $425,064	8,615 New	8,615 $394,000
Q1 2019 May 13, 2019	SELL	$45.12 - $53.8 $181,156 - $216,007	-4,015 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$48.76 - $63.23 $195,771 - $253,868	4,015 New	4,015 $209,000

2,536

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $126B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Flc Capital Advisors, based on Form 13F filings with the SEC.

Stay updated on Flc Capital Advisors with notifications on news.